Carvedilol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Carvedilol: From Hypertension to Malignant Hypertensive Renal Disease
One-Sentence Summary
Carvedilol is a beta-blocker with additional alpha-1 blocking and vasodilating activity, originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but no clinical trials and no publications currently support this specific prediction. The top-ranked prediction is largely an extension of the existing hypertension indication, so the evidence is model-based only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (hypertensive disorder). No approved indication text is available in the Singapore licence records. |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, carvedilol is a non-selective beta-blocker with alpha-1 blockade and vasodilating properties. This lowers blood pressure, which is the basis of its use in hypertension.
Malignant hypertensive renal disease and malignant renovascular hypertension are severe forms of hypertensive disease. A blood pressure-lowering rationale therefore exists. However, the very high TxGNN scores (about 99.5%) most likely reflect closeness to the original hypertension indication in the knowledge graph. They are not independent evidence of benefit in these severe conditions.
Other predictions in the list have more literature but weaker links:
- Pulmonary hypertension owing to lung disease/hypoxia (score 99.54%, L4): only indirect preclinical data, such as carvedilol reversing hypoxia-induced hypertension in rats. Non-selective beta-blockade also carries a theoretical respiratory risk.
- Chronic pulmonary heart disease (score 94.55%, L3): mostly observational data on carvedilol tolerability in heart failure patients with COPD, which is a safety question rather than evidence of efficacy.
- Cerebrovascular disorder (score 68.08%, L4): preclinical neuroprotective and antioxidant findings only.
Clinical Trial Evidence
No clinical trials are registered for the top-ranked prediction (malignant hypertensive renal disease). The trials below were found for lower-ranked predictions and are only indirectly related.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00517725 | Phase 4 | Completed | 60 | Nebivolol vs bisoprolol vs carvedilol in heart failure: effects on exercise capacity, hypoxia, chemoreceptor response and lung function (chronic pulmonary heart disease) |
| NCT00384566 | Phase 4 | Withdrawn | 0 | CAMERA study comparing respiratory effects of carvedilol and metoprolol in heart failure; no data because no patients were enrolled (chronic pulmonary heart disease) |
| NCT00741585 | Phase 4 | Completed | 21,983 | HYGIA study of circadian ambulatory blood pressure patterns and risk. It is not specific to carvedilol (cerebrovascular disorder) |
Literature Evidence
No literature was found for the top-ranked prediction. The most relevant publications for lower-ranked predictions are listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22015086 | 2011 | Randomised trial | Respiratory Medicine | Bisoprolol vs carvedilol in patients with chronic heart failure and COPD |
| 20413026 | 2010 | Randomised crossover trial | J Am Coll Cardiol | Switching between beta1-selective and non-selective beta-blockers in heart failure with COPD |
| 17336720 | 2007 | Post-hoc RCT analysis (COMET) | J Am Coll Cardiol | Carvedilol protected better against vascular events than metoprolol in heart failure |
| 32000982 | 2020 | Cohort | Am J Cardiol | Carvedilol vs metoprolol in elderly patients with heart failure, COPD, diabetes and renal failure |
| 26844454 | 2016 | Cohort | Medicine | Survival effects of carvedilol, bisoprolol and metoprolol in heart failure with COPD (Taiwan database) |
| 12490274 | 2002 | Clinical study | J Heart Lung Transplant | Tolerability of carvedilol in heart failure with COPD or asthma |
| 31544227 | 2019 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Perioperative beta-blockers in cardiac surgery |
| 26291659 | 2015 | Preclinical (animal) | Eur J Pharmacol | Carvedilol reversed hypertension induced by chronic intermittent hypoxia in rats |
| 10950380 | 2000 | Preclinical (animal) | J Cereb Blood Flow Metab | Carvedilol provided neuroprotection in transient focal stroke |
| 36219954 | 2023 | Preclinical (in vitro) | Dev Neurosci | Carvedilol reduced neuronal apoptosis after ischaemic stroke through STAT3 modulation |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13155P | Carvedilol Sandoz 6.25mg | Tablet | Not stated in the licence record |
| SIN13156P | Carvedilol Sandoz 25mg | Tablet | Not stated in the licence record |
| SIN14643P | Vacodil 12.5 Film-coated Tablet 12.5 mg | Film-coated tablet | Not stated in the licence record |
| SIN10335P | Dilatrend Tablet 12.5 mg | Tablet | Not stated in the licence record |
| SIN07421P | Dilatrend Tablet 25 mg | Tablet | Not stated in the licence record |
Seven single-ingredient licences are valid in total. The two further Vacodil licences (6.25 mg, SIN14644P, and 25 mg, SIN14642P) are not shown in the table. All products are oral tablets.
Safety Considerations
- Contraindications flagged in the knowledge graph (these come from the TxGNN knowledge graph, not from package insert text):
- Respiratory: asthma (including intrinsic and allergic asthma), bronchitis, pulmonary emphysema, bronchial disease
- Cardiac conduction: atrioventricular block, sick sinus syndrome (including the familial form)
- Circulatory: hypotensive disorder, peripheral vascular and arterial disease, intermittent claudication, Prinzmetal angina
- Metabolic: diabetes mellitus, diabetic ketoacidosis
- Other: liver failure, anaphylaxis, intraoperative floppy iris syndrome
- Relevance to the predictions: non-selective beta-blockade is a particular concern in the pulmonary hypertension and lung disease predictions, because of respiratory risk and possible harm to right ventricular function.
- Drug interactions: 100 interactions were recorded. The one rated Major is epinephrine. Examples rated Moderate include corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), atropine and hyoscyamine, bupropion, morphine, canagliflozin and acetohexamide, and calcium salts. Aspirin and aluminium hydroxide are rated Minor.
Please refer to the package insert for full warnings and contraindications, as this information could not be retrieved for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The top predictions (malignant hypertensive renal disease and malignant renovascular hypertension) have no trials or literature and mainly reflect closeness to the existing hypertension indication. The predictions with some evidence (pulmonary heart disease, cerebrovascular disorder) rest on indirect observational or preclinical data, and some carry respiratory safety concerns. None reaches the level needed to justify a repurposing programme now.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Mechanism of action data for carvedilol
- Targeted searches for clinical data on carvedilol in hypertensive renal disease and renovascular hypertension
- Confirmation of whether these predictions represent genuinely new indications or only a restatement of the current hypertension use
- For the cerebrovascular and pulmonary directions: well-designed clinical studies and a respiratory and haemodynamic safety assessment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.